ENDOCRINE-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2206111, encodeId=9386220611125, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：甲状腺 经验分享：12月投稿，3月收到小修意见，4月接受，4月底在线发表，编辑挺好的，回复信件很积极。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb78349074, createdName=ms9000001461313699, createdTime=Wed May 22 23:07:39 CST 2024, time=2024-05-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2207618, encodeId=6ceb220e61803, content=1.23 peer review至今＼(`Δ’)／, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=水逆退散～, createdTime=Fri May 31 12:41:32 CST 2024, time=2024-05-31, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2184080, encodeId=993721840805e, content=偏重的研究方向：甲状腺 经验分享：2024.1.25 editor appointed, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=水逆退散～, createdTime=Fri Jan 26 11:40:47 CST 2024, time=2024-01-26, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2207388, encodeId=2c1a220e388cd, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：代谢 经验分享：2024.3.9 submit 2024.3.11 peer review 2024.4.19 返修 2024.4.30 修回 2024.5.29 accept 值得投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13069193199, createdName=ms6000000830172102, createdTime=Thu May 30 10:50:44 CST 2024, time=2024-05-30, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2189418, encodeId=64d7218941826, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：期刊转投，副主编和独立审稿人各一个审稿。 23.11.13 submit 23.11.15 with editor 23.11.16 under review 23.11.17 under review（审稿人接受审稿） 23.12.17 under review（第一个审稿意见） 23.12.19 under review（第二个审稿人） 24.1.19 required reviews completed（第二个审稿意见） 24.1.21 decision in process 24.1.22 major revision 24.2.2 revision submit 24.2.3 with editor 24.2.4 under review 24.2.5 required reviews completed / decision in process 24.2.6 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21888273920, createdName=ms5000000066723286, createdTime=Mon Feb 26 11:07:51 CST 2024, time=2024-02-26, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2201654, encodeId=57ad220165431, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺肿瘤 经验分享：2月9号投稿 3月13号返修只有一个审稿人修了2周修回去，4月初接受，责任编辑是主编，权利大，人很好，接受后会先proof，然后问你要不要交版面费。值得投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7175494638, createdName=ms6000000585377014, createdTime=Sat May 04 00:07:31 CST 2024, time=2024-05-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199958, encodeId=2bed2199958f3, content=投稿系统里的article type没有original article，各位都是选择什么选项投稿的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5282129934, createdName=zhangly92, createdTime=Tue Apr 23 14:59:42 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199959, encodeId=19812199959c0, content=问下投稿时选择article type，没有originl article 这个选项，都选择的是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5282129934, createdName=zhangly92, createdTime=Tue Apr 23 15:08:20 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2198589, encodeId=40032198589dc, content=请问一般多久online呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e7c5623450, createdName=ms5000001120338885, createdTime=Mon Apr 15 12:16:42 CST 2024, time=2024-04-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2197423, encodeId=d521219e4230e, content=请问Technical check后面是Peer review，Peer review已经持续一个月了，是送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13069193199, createdName=ms6000000830172102, createdTime=Mon Apr 08 17:37:43 CST 2024, time=2024-04-08, status=1, ipAttribution=安徽省)]

2024-05-22 ms9000001461313699 来自广东省

审稿速度:6.0 | 投稿命中率:75.0
偏重的研究方向：甲状腺
经验分享：12月投稿，3月收到小修意见，4月接受，4月底在线发表，编辑挺好的，回复信件很积极。

0 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2206111, encodeId=9386220611125, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：甲状腺 经验分享：12月投稿，3月收到小修意见，4月接受，4月底在线发表，编辑挺好的，回复信件很积极。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb78349074, createdName=ms9000001461313699, createdTime=Wed May 22 23:07:39 CST 2024, time=2024-05-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2207618, encodeId=6ceb220e61803, content=1.23 peer review至今＼(`Δ’)／, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=水逆退散～, createdTime=Fri May 31 12:41:32 CST 2024, time=2024-05-31, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2184080, encodeId=993721840805e, content=偏重的研究方向：甲状腺 经验分享：2024.1.25 editor appointed, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=水逆退散～, createdTime=Fri Jan 26 11:40:47 CST 2024, time=2024-01-26, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2207388, encodeId=2c1a220e388cd, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：代谢 经验分享：2024.3.9 submit 2024.3.11 peer review 2024.4.19 返修 2024.4.30 修回 2024.5.29 accept 值得投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13069193199, createdName=ms6000000830172102, createdTime=Thu May 30 10:50:44 CST 2024, time=2024-05-30, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2189418, encodeId=64d7218941826, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：期刊转投，副主编和独立审稿人各一个审稿。 23.11.13 submit 23.11.15 with editor 23.11.16 under review 23.11.17 under review（审稿人接受审稿） 23.12.17 under review（第一个审稿意见） 23.12.19 under review（第二个审稿人） 24.1.19 required reviews completed（第二个审稿意见） 24.1.21 decision in process 24.1.22 major revision 24.2.2 revision submit 24.2.3 with editor 24.2.4 under review 24.2.5 required reviews completed / decision in process 24.2.6 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21888273920, createdName=ms5000000066723286, createdTime=Mon Feb 26 11:07:51 CST 2024, time=2024-02-26, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2201654, encodeId=57ad220165431, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺肿瘤 经验分享：2月9号投稿 3月13号返修只有一个审稿人修了2周修回去，4月初接受，责任编辑是主编，权利大，人很好，接受后会先proof，然后问你要不要交版面费。值得投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7175494638, createdName=ms6000000585377014, createdTime=Sat May 04 00:07:31 CST 2024, time=2024-05-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199958, encodeId=2bed2199958f3, content=投稿系统里的article type没有original article，各位都是选择什么选项投稿的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5282129934, createdName=zhangly92, createdTime=Tue Apr 23 14:59:42 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199959, encodeId=19812199959c0, content=问下投稿时选择article type，没有originl article 这个选项，都选择的是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5282129934, createdName=zhangly92, createdTime=Tue Apr 23 15:08:20 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2198589, encodeId=40032198589dc, content=请问一般多久online呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e7c5623450, createdName=ms5000001120338885, createdTime=Mon Apr 15 12:16:42 CST 2024, time=2024-04-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2197423, encodeId=d521219e4230e, content=请问Technical check后面是Peer review，Peer review已经持续一个月了，是送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13069193199, createdName=ms6000000830172102, createdTime=Mon Apr 08 17:37:43 CST 2024, time=2024-04-08, status=1, ipAttribution=安徽省)]

2024-05-31 水逆退散～来自广西

1.23 peer review至今＼(`Δ’)／

20 0

[GetPortalCommentsPageByObjectIdResponse(id=2206111, encodeId=9386220611125, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：甲状腺 经验分享：12月投稿，3月收到小修意见，4月接受，4月底在线发表，编辑挺好的，回复信件很积极。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb78349074, createdName=ms9000001461313699, createdTime=Wed May 22 23:07:39 CST 2024, time=2024-05-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2207618, encodeId=6ceb220e61803, content=1.23 peer review至今＼(`Δ’)／, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=水逆退散～, createdTime=Fri May 31 12:41:32 CST 2024, time=2024-05-31, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2184080, encodeId=993721840805e, content=偏重的研究方向：甲状腺 经验分享：2024.1.25 editor appointed, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=水逆退散～, createdTime=Fri Jan 26 11:40:47 CST 2024, time=2024-01-26, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2207388, encodeId=2c1a220e388cd, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：代谢 经验分享：2024.3.9 submit 2024.3.11 peer review 2024.4.19 返修 2024.4.30 修回 2024.5.29 accept 值得投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13069193199, createdName=ms6000000830172102, createdTime=Thu May 30 10:50:44 CST 2024, time=2024-05-30, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2189418, encodeId=64d7218941826, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：期刊转投，副主编和独立审稿人各一个审稿。 23.11.13 submit 23.11.15 with editor 23.11.16 under review 23.11.17 under review（审稿人接受审稿） 23.12.17 under review（第一个审稿意见） 23.12.19 under review（第二个审稿人） 24.1.19 required reviews completed（第二个审稿意见） 24.1.21 decision in process 24.1.22 major revision 24.2.2 revision submit 24.2.3 with editor 24.2.4 under review 24.2.5 required reviews completed / decision in process 24.2.6 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21888273920, createdName=ms5000000066723286, createdTime=Mon Feb 26 11:07:51 CST 2024, time=2024-02-26, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2201654, encodeId=57ad220165431, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺肿瘤 经验分享：2月9号投稿 3月13号返修只有一个审稿人修了2周修回去，4月初接受，责任编辑是主编，权利大，人很好，接受后会先proof，然后问你要不要交版面费。值得投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7175494638, createdName=ms6000000585377014, createdTime=Sat May 04 00:07:31 CST 2024, time=2024-05-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199958, encodeId=2bed2199958f3, content=投稿系统里的article type没有original article，各位都是选择什么选项投稿的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5282129934, createdName=zhangly92, createdTime=Tue Apr 23 14:59:42 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199959, encodeId=19812199959c0, content=问下投稿时选择article type，没有originl article 这个选项，都选择的是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5282129934, createdName=zhangly92, createdTime=Tue Apr 23 15:08:20 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2198589, encodeId=40032198589dc, content=请问一般多久online呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e7c5623450, createdName=ms5000001120338885, createdTime=Mon Apr 15 12:16:42 CST 2024, time=2024-04-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2197423, encodeId=d521219e4230e, content=请问Technical check后面是Peer review，Peer review已经持续一个月了，是送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13069193199, createdName=ms6000000830172102, createdTime=Mon Apr 08 17:37:43 CST 2024, time=2024-04-08, status=1, ipAttribution=安徽省)]

2024-01-26 水逆退散～来自广西

偏重的研究方向：甲状腺
经验分享：2024.1.25 editor appointed

50 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2206111, encodeId=9386220611125, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：甲状腺 经验分享：12月投稿，3月收到小修意见，4月接受，4月底在线发表，编辑挺好的，回复信件很积极。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb78349074, createdName=ms9000001461313699, createdTime=Wed May 22 23:07:39 CST 2024, time=2024-05-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2207618, encodeId=6ceb220e61803, content=1.23 peer review至今＼(`Δ’)／, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=水逆退散～, createdTime=Fri May 31 12:41:32 CST 2024, time=2024-05-31, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2184080, encodeId=993721840805e, content=偏重的研究方向：甲状腺 经验分享：2024.1.25 editor appointed, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=水逆退散～, createdTime=Fri Jan 26 11:40:47 CST 2024, time=2024-01-26, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2207388, encodeId=2c1a220e388cd, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：代谢 经验分享：2024.3.9 submit 2024.3.11 peer review 2024.4.19 返修 2024.4.30 修回 2024.5.29 accept 值得投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13069193199, createdName=ms6000000830172102, createdTime=Thu May 30 10:50:44 CST 2024, time=2024-05-30, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2189418, encodeId=64d7218941826, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：期刊转投，副主编和独立审稿人各一个审稿。 23.11.13 submit 23.11.15 with editor 23.11.16 under review 23.11.17 under review（审稿人接受审稿） 23.12.17 under review（第一个审稿意见） 23.12.19 under review（第二个审稿人） 24.1.19 required reviews completed（第二个审稿意见） 24.1.21 decision in process 24.1.22 major revision 24.2.2 revision submit 24.2.3 with editor 24.2.4 under review 24.2.5 required reviews completed / decision in process 24.2.6 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21888273920, createdName=ms5000000066723286, createdTime=Mon Feb 26 11:07:51 CST 2024, time=2024-02-26, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2201654, encodeId=57ad220165431, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺肿瘤 经验分享：2月9号投稿 3月13号返修只有一个审稿人修了2周修回去，4月初接受，责任编辑是主编，权利大，人很好，接受后会先proof，然后问你要不要交版面费。值得投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7175494638, createdName=ms6000000585377014, createdTime=Sat May 04 00:07:31 CST 2024, time=2024-05-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199958, encodeId=2bed2199958f3, content=投稿系统里的article type没有original article，各位都是选择什么选项投稿的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5282129934, createdName=zhangly92, createdTime=Tue Apr 23 14:59:42 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199959, encodeId=19812199959c0, content=问下投稿时选择article type，没有originl article 这个选项，都选择的是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5282129934, createdName=zhangly92, createdTime=Tue Apr 23 15:08:20 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2198589, encodeId=40032198589dc, content=请问一般多久online呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e7c5623450, createdName=ms5000001120338885, createdTime=Mon Apr 15 12:16:42 CST 2024, time=2024-04-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2197423, encodeId=d521219e4230e, content=请问Technical check后面是Peer review，Peer review已经持续一个月了，是送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13069193199, createdName=ms6000000830172102, createdTime=Mon Apr 08 17:37:43 CST 2024, time=2024-04-08, status=1, ipAttribution=安徽省)]

2024-05-30 ms6000000830172102 来自安徽省

审稿速度:3.0 | 投稿命中率:75.0
偏重的研究方向：代谢
经验分享：2024.3.9 submit
2024.3.11 peer review
2024.4.19 返修
2024.4.30 修回
2024.5.29 accept
值得投

32 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2206111, encodeId=9386220611125, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：甲状腺 经验分享：12月投稿，3月收到小修意见，4月接受，4月底在线发表，编辑挺好的，回复信件很积极。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb78349074, createdName=ms9000001461313699, createdTime=Wed May 22 23:07:39 CST 2024, time=2024-05-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2207618, encodeId=6ceb220e61803, content=1.23 peer review至今＼(`Δ’)／, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=水逆退散～, createdTime=Fri May 31 12:41:32 CST 2024, time=2024-05-31, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2184080, encodeId=993721840805e, content=偏重的研究方向：甲状腺 经验分享：2024.1.25 editor appointed, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=水逆退散～, createdTime=Fri Jan 26 11:40:47 CST 2024, time=2024-01-26, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2207388, encodeId=2c1a220e388cd, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：代谢 经验分享：2024.3.9 submit 2024.3.11 peer review 2024.4.19 返修 2024.4.30 修回 2024.5.29 accept 值得投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13069193199, createdName=ms6000000830172102, createdTime=Thu May 30 10:50:44 CST 2024, time=2024-05-30, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2189418, encodeId=64d7218941826, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：期刊转投，副主编和独立审稿人各一个审稿。 23.11.13 submit 23.11.15 with editor 23.11.16 under review 23.11.17 under review（审稿人接受审稿） 23.12.17 under review（第一个审稿意见） 23.12.19 under review（第二个审稿人） 24.1.19 required reviews completed（第二个审稿意见） 24.1.21 decision in process 24.1.22 major revision 24.2.2 revision submit 24.2.3 with editor 24.2.4 under review 24.2.5 required reviews completed / decision in process 24.2.6 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21888273920, createdName=ms5000000066723286, createdTime=Mon Feb 26 11:07:51 CST 2024, time=2024-02-26, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2201654, encodeId=57ad220165431, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺肿瘤 经验分享：2月9号投稿 3月13号返修只有一个审稿人修了2周修回去，4月初接受，责任编辑是主编，权利大，人很好，接受后会先proof，然后问你要不要交版面费。值得投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7175494638, createdName=ms6000000585377014, createdTime=Sat May 04 00:07:31 CST 2024, time=2024-05-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199958, encodeId=2bed2199958f3, content=投稿系统里的article type没有original article，各位都是选择什么选项投稿的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5282129934, createdName=zhangly92, createdTime=Tue Apr 23 14:59:42 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199959, encodeId=19812199959c0, content=问下投稿时选择article type，没有originl article 这个选项，都选择的是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5282129934, createdName=zhangly92, createdTime=Tue Apr 23 15:08:20 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2198589, encodeId=40032198589dc, content=请问一般多久online呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e7c5623450, createdName=ms5000001120338885, createdTime=Mon Apr 15 12:16:42 CST 2024, time=2024-04-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2197423, encodeId=d521219e4230e, content=请问Technical check后面是Peer review，Peer review已经持续一个月了，是送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13069193199, createdName=ms6000000830172102, createdTime=Mon Apr 08 17:37:43 CST 2024, time=2024-04-08, status=1, ipAttribution=安徽省)]

2024-02-26 ms5000000066723286 来自江苏省

审稿速度:1.0
偏重的研究方向：糖尿病
经验分享：期刊转投，副主编和独立审稿人各一个审稿。 23.11.13 submit 23.11.15 with editor 23.11.16 under review 23.11.17 under review（审稿人接受审稿） 23.12.17 under review（第一个审稿意见） 23.12.19 under review（第二个审稿人） 24.1.19 required reviews completed（第二个审稿意见） 24.1.21 decision in process 24.1.22 major revision 24.2.2 revision submit 24.2.3 with editor 24.2.4 under review 24.2.5 required reviews completed / decision in process 24.2.6 accept

73 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2206111, encodeId=9386220611125, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：甲状腺 经验分享：12月投稿，3月收到小修意见，4月接受，4月底在线发表，编辑挺好的，回复信件很积极。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb78349074, createdName=ms9000001461313699, createdTime=Wed May 22 23:07:39 CST 2024, time=2024-05-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2207618, encodeId=6ceb220e61803, content=1.23 peer review至今＼(`Δ’)／, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=水逆退散～, createdTime=Fri May 31 12:41:32 CST 2024, time=2024-05-31, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2184080, encodeId=993721840805e, content=偏重的研究方向：甲状腺 经验分享：2024.1.25 editor appointed, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=水逆退散～, createdTime=Fri Jan 26 11:40:47 CST 2024, time=2024-01-26, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2207388, encodeId=2c1a220e388cd, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：代谢 经验分享：2024.3.9 submit 2024.3.11 peer review 2024.4.19 返修 2024.4.30 修回 2024.5.29 accept 值得投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13069193199, createdName=ms6000000830172102, createdTime=Thu May 30 10:50:44 CST 2024, time=2024-05-30, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2189418, encodeId=64d7218941826, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：期刊转投，副主编和独立审稿人各一个审稿。 23.11.13 submit 23.11.15 with editor 23.11.16 under review 23.11.17 under review（审稿人接受审稿） 23.12.17 under review（第一个审稿意见） 23.12.19 under review（第二个审稿人） 24.1.19 required reviews completed（第二个审稿意见） 24.1.21 decision in process 24.1.22 major revision 24.2.2 revision submit 24.2.3 with editor 24.2.4 under review 24.2.5 required reviews completed / decision in process 24.2.6 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21888273920, createdName=ms5000000066723286, createdTime=Mon Feb 26 11:07:51 CST 2024, time=2024-02-26, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2201654, encodeId=57ad220165431, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺肿瘤 经验分享：2月9号投稿 3月13号返修只有一个审稿人修了2周修回去，4月初接受，责任编辑是主编，权利大，人很好，接受后会先proof，然后问你要不要交版面费。值得投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7175494638, createdName=ms6000000585377014, createdTime=Sat May 04 00:07:31 CST 2024, time=2024-05-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199958, encodeId=2bed2199958f3, content=投稿系统里的article type没有original article，各位都是选择什么选项投稿的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5282129934, createdName=zhangly92, createdTime=Tue Apr 23 14:59:42 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199959, encodeId=19812199959c0, content=问下投稿时选择article type，没有originl article 这个选项，都选择的是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5282129934, createdName=zhangly92, createdTime=Tue Apr 23 15:08:20 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2198589, encodeId=40032198589dc, content=请问一般多久online呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e7c5623450, createdName=ms5000001120338885, createdTime=Mon Apr 15 12:16:42 CST 2024, time=2024-04-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2197423, encodeId=d521219e4230e, content=请问Technical check后面是Peer review，Peer review已经持续一个月了，是送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13069193199, createdName=ms6000000830172102, createdTime=Mon Apr 08 17:37:43 CST 2024, time=2024-04-08, status=1, ipAttribution=安徽省)]

2024-05-04 ms6000000585377014 来自广东省

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：甲状腺肿瘤
经验分享：2月9号投稿 3月13号返修只有一个审稿人修了2周修回去，4月初接受，责任编辑是主编，权利大，人很好，接受后会先proof，然后问你要不要交版面费。值得投

27 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2206111, encodeId=9386220611125, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：甲状腺 经验分享：12月投稿，3月收到小修意见，4月接受，4月底在线发表，编辑挺好的，回复信件很积极。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb78349074, createdName=ms9000001461313699, createdTime=Wed May 22 23:07:39 CST 2024, time=2024-05-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2207618, encodeId=6ceb220e61803, content=1.23 peer review至今＼(`Δ’)／, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=水逆退散～, createdTime=Fri May 31 12:41:32 CST 2024, time=2024-05-31, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2184080, encodeId=993721840805e, content=偏重的研究方向：甲状腺 经验分享：2024.1.25 editor appointed, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=水逆退散～, createdTime=Fri Jan 26 11:40:47 CST 2024, time=2024-01-26, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2207388, encodeId=2c1a220e388cd, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：代谢 经验分享：2024.3.9 submit 2024.3.11 peer review 2024.4.19 返修 2024.4.30 修回 2024.5.29 accept 值得投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13069193199, createdName=ms6000000830172102, createdTime=Thu May 30 10:50:44 CST 2024, time=2024-05-30, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2189418, encodeId=64d7218941826, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：期刊转投，副主编和独立审稿人各一个审稿。 23.11.13 submit 23.11.15 with editor 23.11.16 under review 23.11.17 under review（审稿人接受审稿） 23.12.17 under review（第一个审稿意见） 23.12.19 under review（第二个审稿人） 24.1.19 required reviews completed（第二个审稿意见） 24.1.21 decision in process 24.1.22 major revision 24.2.2 revision submit 24.2.3 with editor 24.2.4 under review 24.2.5 required reviews completed / decision in process 24.2.6 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21888273920, createdName=ms5000000066723286, createdTime=Mon Feb 26 11:07:51 CST 2024, time=2024-02-26, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2201654, encodeId=57ad220165431, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺肿瘤 经验分享：2月9号投稿 3月13号返修只有一个审稿人修了2周修回去，4月初接受，责任编辑是主编，权利大，人很好，接受后会先proof，然后问你要不要交版面费。值得投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7175494638, createdName=ms6000000585377014, createdTime=Sat May 04 00:07:31 CST 2024, time=2024-05-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199958, encodeId=2bed2199958f3, content=投稿系统里的article type没有original article，各位都是选择什么选项投稿的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5282129934, createdName=zhangly92, createdTime=Tue Apr 23 14:59:42 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199959, encodeId=19812199959c0, content=问下投稿时选择article type，没有originl article 这个选项，都选择的是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5282129934, createdName=zhangly92, createdTime=Tue Apr 23 15:08:20 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2198589, encodeId=40032198589dc, content=请问一般多久online呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e7c5623450, createdName=ms5000001120338885, createdTime=Mon Apr 15 12:16:42 CST 2024, time=2024-04-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2197423, encodeId=d521219e4230e, content=请问Technical check后面是Peer review，Peer review已经持续一个月了，是送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13069193199, createdName=ms6000000830172102, createdTime=Mon Apr 08 17:37:43 CST 2024, time=2024-04-08, status=1, ipAttribution=安徽省)]

2024-04-23 zhangly92 来自广东省

投稿系统里的article type没有original article，各位都是选择什么选项投稿的？

25 0

[GetPortalCommentsPageByObjectIdResponse(id=2206111, encodeId=9386220611125, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：甲状腺 经验分享：12月投稿，3月收到小修意见，4月接受，4月底在线发表，编辑挺好的，回复信件很积极。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb78349074, createdName=ms9000001461313699, createdTime=Wed May 22 23:07:39 CST 2024, time=2024-05-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2207618, encodeId=6ceb220e61803, content=1.23 peer review至今＼(`Δ’)／, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=水逆退散～, createdTime=Fri May 31 12:41:32 CST 2024, time=2024-05-31, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2184080, encodeId=993721840805e, content=偏重的研究方向：甲状腺 经验分享：2024.1.25 editor appointed, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=水逆退散～, createdTime=Fri Jan 26 11:40:47 CST 2024, time=2024-01-26, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2207388, encodeId=2c1a220e388cd, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：代谢 经验分享：2024.3.9 submit 2024.3.11 peer review 2024.4.19 返修 2024.4.30 修回 2024.5.29 accept 值得投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13069193199, createdName=ms6000000830172102, createdTime=Thu May 30 10:50:44 CST 2024, time=2024-05-30, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2189418, encodeId=64d7218941826, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：期刊转投，副主编和独立审稿人各一个审稿。 23.11.13 submit 23.11.15 with editor 23.11.16 under review 23.11.17 under review（审稿人接受审稿） 23.12.17 under review（第一个审稿意见） 23.12.19 under review（第二个审稿人） 24.1.19 required reviews completed（第二个审稿意见） 24.1.21 decision in process 24.1.22 major revision 24.2.2 revision submit 24.2.3 with editor 24.2.4 under review 24.2.5 required reviews completed / decision in process 24.2.6 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21888273920, createdName=ms5000000066723286, createdTime=Mon Feb 26 11:07:51 CST 2024, time=2024-02-26, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2201654, encodeId=57ad220165431, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺肿瘤 经验分享：2月9号投稿 3月13号返修只有一个审稿人修了2周修回去，4月初接受，责任编辑是主编，权利大，人很好，接受后会先proof，然后问你要不要交版面费。值得投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7175494638, createdName=ms6000000585377014, createdTime=Sat May 04 00:07:31 CST 2024, time=2024-05-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199958, encodeId=2bed2199958f3, content=投稿系统里的article type没有original article，各位都是选择什么选项投稿的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5282129934, createdName=zhangly92, createdTime=Tue Apr 23 14:59:42 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199959, encodeId=19812199959c0, content=问下投稿时选择article type，没有originl article 这个选项，都选择的是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5282129934, createdName=zhangly92, createdTime=Tue Apr 23 15:08:20 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2198589, encodeId=40032198589dc, content=请问一般多久online呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e7c5623450, createdName=ms5000001120338885, createdTime=Mon Apr 15 12:16:42 CST 2024, time=2024-04-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2197423, encodeId=d521219e4230e, content=请问Technical check后面是Peer review，Peer review已经持续一个月了，是送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13069193199, createdName=ms6000000830172102, createdTime=Mon Apr 08 17:37:43 CST 2024, time=2024-04-08, status=1, ipAttribution=安徽省)]

2024-04-23 zhangly92 来自广东省

问下投稿时选择article type，没有originl article 这个选项，都选择的是什么？

25 0

[GetPortalCommentsPageByObjectIdResponse(id=2206111, encodeId=9386220611125, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：甲状腺 经验分享：12月投稿，3月收到小修意见，4月接受，4月底在线发表，编辑挺好的，回复信件很积极。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb78349074, createdName=ms9000001461313699, createdTime=Wed May 22 23:07:39 CST 2024, time=2024-05-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2207618, encodeId=6ceb220e61803, content=1.23 peer review至今＼(`Δ’)／, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=水逆退散～, createdTime=Fri May 31 12:41:32 CST 2024, time=2024-05-31, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2184080, encodeId=993721840805e, content=偏重的研究方向：甲状腺 经验分享：2024.1.25 editor appointed, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=水逆退散～, createdTime=Fri Jan 26 11:40:47 CST 2024, time=2024-01-26, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2207388, encodeId=2c1a220e388cd, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：代谢 经验分享：2024.3.9 submit 2024.3.11 peer review 2024.4.19 返修 2024.4.30 修回 2024.5.29 accept 值得投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13069193199, createdName=ms6000000830172102, createdTime=Thu May 30 10:50:44 CST 2024, time=2024-05-30, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2189418, encodeId=64d7218941826, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：期刊转投，副主编和独立审稿人各一个审稿。 23.11.13 submit 23.11.15 with editor 23.11.16 under review 23.11.17 under review（审稿人接受审稿） 23.12.17 under review（第一个审稿意见） 23.12.19 under review（第二个审稿人） 24.1.19 required reviews completed（第二个审稿意见） 24.1.21 decision in process 24.1.22 major revision 24.2.2 revision submit 24.2.3 with editor 24.2.4 under review 24.2.5 required reviews completed / decision in process 24.2.6 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21888273920, createdName=ms5000000066723286, createdTime=Mon Feb 26 11:07:51 CST 2024, time=2024-02-26, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2201654, encodeId=57ad220165431, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺肿瘤 经验分享：2月9号投稿 3月13号返修只有一个审稿人修了2周修回去，4月初接受，责任编辑是主编，权利大，人很好，接受后会先proof，然后问你要不要交版面费。值得投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7175494638, createdName=ms6000000585377014, createdTime=Sat May 04 00:07:31 CST 2024, time=2024-05-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199958, encodeId=2bed2199958f3, content=投稿系统里的article type没有original article，各位都是选择什么选项投稿的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5282129934, createdName=zhangly92, createdTime=Tue Apr 23 14:59:42 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199959, encodeId=19812199959c0, content=问下投稿时选择article type，没有originl article 这个选项，都选择的是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5282129934, createdName=zhangly92, createdTime=Tue Apr 23 15:08:20 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2198589, encodeId=40032198589dc, content=请问一般多久online呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e7c5623450, createdName=ms5000001120338885, createdTime=Mon Apr 15 12:16:42 CST 2024, time=2024-04-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2197423, encodeId=d521219e4230e, content=请问Technical check后面是Peer review，Peer review已经持续一个月了，是送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13069193199, createdName=ms6000000830172102, createdTime=Mon Apr 08 17:37:43 CST 2024, time=2024-04-08, status=1, ipAttribution=安徽省)]

2024-04-15 ms5000001120338885 来自重庆

请问一般多久online呀

28 0

[GetPortalCommentsPageByObjectIdResponse(id=2206111, encodeId=9386220611125, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：甲状腺 经验分享：12月投稿，3月收到小修意见，4月接受，4月底在线发表，编辑挺好的，回复信件很积极。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb78349074, createdName=ms9000001461313699, createdTime=Wed May 22 23:07:39 CST 2024, time=2024-05-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2207618, encodeId=6ceb220e61803, content=1.23 peer review至今＼(`Δ’)／, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=水逆退散～, createdTime=Fri May 31 12:41:32 CST 2024, time=2024-05-31, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2184080, encodeId=993721840805e, content=偏重的研究方向：甲状腺 经验分享：2024.1.25 editor appointed, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/03e641e496f246868d0a685a1c4c9c9c/400a16594e81429fa2005190467547ef.jpg, createdBy=9c375406070, createdName=水逆退散～, createdTime=Fri Jan 26 11:40:47 CST 2024, time=2024-01-26, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2207388, encodeId=2c1a220e388cd, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：代谢 经验分享：2024.3.9 submit 2024.3.11 peer review 2024.4.19 返修 2024.4.30 修回 2024.5.29 accept 值得投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13069193199, createdName=ms6000000830172102, createdTime=Thu May 30 10:50:44 CST 2024, time=2024-05-30, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2189418, encodeId=64d7218941826, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：期刊转投，副主编和独立审稿人各一个审稿。 23.11.13 submit 23.11.15 with editor 23.11.16 under review 23.11.17 under review（审稿人接受审稿） 23.12.17 under review（第一个审稿意见） 23.12.19 under review（第二个审稿人） 24.1.19 required reviews completed（第二个审稿意见） 24.1.21 decision in process 24.1.22 major revision 24.2.2 revision submit 24.2.3 with editor 24.2.4 under review 24.2.5 required reviews completed / decision in process 24.2.6 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21888273920, createdName=ms5000000066723286, createdTime=Mon Feb 26 11:07:51 CST 2024, time=2024-02-26, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2201654, encodeId=57ad220165431, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺肿瘤 经验分享：2月9号投稿 3月13号返修只有一个审稿人修了2周修回去，4月初接受，责任编辑是主编，权利大，人很好，接受后会先proof，然后问你要不要交版面费。值得投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7175494638, createdName=ms6000000585377014, createdTime=Sat May 04 00:07:31 CST 2024, time=2024-05-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199958, encodeId=2bed2199958f3, content=投稿系统里的article type没有original article，各位都是选择什么选项投稿的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5282129934, createdName=zhangly92, createdTime=Tue Apr 23 14:59:42 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199959, encodeId=19812199959c0, content=问下投稿时选择article type，没有originl article 这个选项，都选择的是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5282129934, createdName=zhangly92, createdTime=Tue Apr 23 15:08:20 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2198589, encodeId=40032198589dc, content=请问一般多久online呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e7c5623450, createdName=ms5000001120338885, createdTime=Mon Apr 15 12:16:42 CST 2024, time=2024-04-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2197423, encodeId=d521219e4230e, content=请问Technical check后面是Peer review，Peer review已经持续一个月了，是送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13069193199, createdName=ms6000000830172102, createdTime=Mon Apr 08 17:37:43 CST 2024, time=2024-04-08, status=1, ipAttribution=安徽省)]

2024-04-08 ms6000000830172102 来自安徽省

请问Technical check后面是Peer review，Peer review已经持续一个月了，是送审了吗？

45 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务